In the preceding three months, 5 analysts have released ratings for IDEAYA Biosciences (NASDAQ:IDYA), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
3
0
0
0
Last 30D
0
1
0
0
0
1M Ago
0
0
0
0
0
2M Ago
1
0
0
0
0
3M Ago
1
2
0
0
0
The 12-month price targets, analyzed by analysts, offer insights with an average target of $55.4, a high estimate of $60.00, and a low estimate of $52.00. This current average has increased by 24.02% from the previous average price target of $44.67.
Understanding Analyst Ratings: A Comprehensive Breakdown
The analysis of recent analyst actions sheds light on the perception of IDEAYA Biosciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Robert Driscoll
Wedbush
Maintains
Outperform
$52.00
-
Yigal Nochomovitz
Citigroup
Raises
Buy
$60.00
$40.00
Justin Zelin
BTIG
Announces
Buy
$55.00
-
Anupam Rama
JP Morgan
Raises
Overweight
$57.00
$51.00
Gregory Renza
RBC Capital
Raises
Outperform
$53.00
$43.00
Key Insights:
Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to IDEAYA Biosciences. This information provides ...Full story available on Benzinga.com
Benzinga
